Doug Loe: Canada Has Earned Its Spot In The Biotech All-Star Team Photo
Life Sciences Report - Seeking Alpha - Fri Dec 19, 9:53AM CST
Biotech investors in the United States who overlook investment opportunities across the borders are missing out on huge opportunities, says Douglas Loe, healthcare equity analyst with Euro Pacific Canada. In this interview with The Life Sciences...
BIIB: 340.89 (+5.13), VRX: 140.33 (-0.22), QLTI: 3.72 (+0.08), CTRX: 51.83 (+0.14), BCRX: 11.83 (+0.76), ACT: 254.20 (-1.68), MDT: 74.08 (+0.31), TKMR: 13.97 (+0.14), NEPT: 1.88 (+0.03), BSX: 13.13 (+0.07), AGN: 210.12 (+0.95), CMRX: 36.80 (+0.70), ALNY: 93.52 (+0.97), SRPT: 13.88 (+0.47), SHPG: 209.29 (+0.07), NLNK: 39.08 (+1.36), SNY: 46.35 (+0.50), MSLI: 1.67 (+0.02), NVCN: 6.60 (unch), CRME: 8.56 (+0.06), EBS: 27.64 (+1.28), GSK: 42.85 (+0.11), CELG: 109.60 (+3.48), GILD: 91.29 (+1.84), MRK: 57.46 (+0.25), NVDQ: 16.90 (+0.55), NVS: 93.91 (+0.66)
Cardiome Enters Development and Commercialization Agreement with Eddingpharm for BRINAVESS(TM) in China
CNW Group - Fri Dec 19, 7:00AM CST
NASDAQ: CRME TSX: COM
CRME: 8.56 (+0.06), COM.TO: 9.94 (+0.08)
Cardiome Enters Development and Commercialization Agreement with Eddingpharm for BRINAVESS™ in China
PR Newswire - Fri Dec 19, 7:00AM CST
NASDAQ: CRME TSX: COM
CRME: 8.56 (+0.06), COM.TO: 9.94 (+0.08)
Cardiome Enters Commercialization Agreement with Aspen for BRINAVESS® in South Africa
PR Newswire - Mon Nov 17, 7:30AM CST
NASDAQ: CRME TSX: COM
CRME: 8.56 (+0.06), COM.TO: 9.94 (+0.08)
Cardiome Pharma applies for BRINAVESS' reimbursement in Italy for atrial fibrillation
M2 - Mon Nov 10, 7:46AM CST
Pharmaceutical company Cardiome Pharma (NASDAQ:CRME)(TSX:COM) disclosed on Friday that it has submitted its BRINAVESS' reimbursement dossier to the Italian authorities in support of its market launch in the country.
CRME: 8.56 (+0.06), COM.TO: 9.94 (+0.08)
Cardiome Pharma's (CRME) CEO Bill Hunter on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Fri Nov 07, 8:15PM CST
CRME: 8.56 (+0.06)
Cardiome Pharma misses by $0.13, beats on revenue
Seeking Alpha - at Seeking Alpha - Fri Nov 07, 6:22AM CST
CRME: 8.56 (+0.06)
Cardiome Reports Third Quarter 2014 Financial Results
CNW Group - Fri Nov 07, 6:00AM CST
NASDAQ: CRME TSX: COM
CRME: 8.56 (+0.06), COM.TO: 9.94 (+0.08)
Cardiome Submits BRINAVESS® Reimbursement Dossier to Italian Authorities to Support Market Access
PR Newswire - Fri Nov 07, 6:00AM CST
NASDAQ: CRME TSX: COM
CRME: 8.56 (+0.06), COM.TO: 9.94 (+0.08)
Cardiome Announces Positive Results from the BRINAVESS® Asia-Pacific Phase 3 Clinical Trial
PR Newswire - Fri Nov 07, 6:00AM CST
NASDAQ: CRME TSX: COM
CRME: 8.56 (+0.06), COM.TO: 9.94 (+0.08)
Cardiome reports November 7
Seeking Alpha - at Seeking Alpha - Mon Nov 03, 6:17AM CST
CRME: 8.56 (+0.06)
Cardiome to Hold Third Quarter 2014 Financial Results Conference Call on November 7
CNW Group - Fri Oct 31, 1:00PM CDT
NASDAQ: CRME TSX: COM
CRME: 8.56 (+0.06), COM.TO: 9.94 (+0.08)
Uptrend Call Working As Cardiome Pharma Stock Rises 16.2% (CRME)
Comtex SmarTrend(R) - Fri Oct 03, 11:07AM CDT
SmarTrend identified an Uptrend for Cardiome Pharma (NASDAQ:CRME) on August 11th, 2014 at $7.61. In approximately 2 months, Cardiome Pharma has returned 16.24% as of today's recent price of $8.84.
CRME: 8.56 (+0.06)
CARDIOME PHARMA (CRME) Enters Overbought Territory